In-Vitro Toxicology Testing Market by Technology, Method, Application, End-User Industry

Description

List of Tables

[182 Pages Report] The In-Vitro Toxicology Testing Market size was estimated at USD 12.21 billion in 2023 and expected to reach USD 13.49 billion in 2024, at a CAGR 10.90% to reach USD 25.21 billion by 2030.

The in-vitro toxicology testing market employs cell cultures and organ cultures for toxicity evaluation of substances such as chemicals, drugs, and food. This innovative approach, used in pharmaceuticals, cosmetics, and the food industry, offers significant precision, repeatability, and speed benefits. The market is thriving due to advancements in testing methods, a rising ethos against animal testing, and the increased need for cost-effective safety measures. Potential growth areas lie in using in-vitro models in drug and therapeutic development, which closely mimic human biochemistry and minimize the occurrence of unsuccessful clinical trials. Further, the progress in genomics and proteomics presents considerable growth opportunities. The market, however, faces challenges such as the complexity of test data interpretation, the difficulty of replicating in-vivo conditions, and regulatory intricacies, all of which contribute to high operational costs. Future business growth hinges on focused research to enhance the predictive accuracy of in-vitro test systems while lowering costs. Collaborations with regulatory agencies for test recognition and approval advances in computational biology and genomics and innovations in 3D cell culture and organ-on-a-chip systems collectively drive market expansion, ensuring a broad consumer base is achieved while upholding consumer safety standards.

KEY MARKET STATISTICS
Base Year [2023]	USD 12.21 billion
Estimated Year [2024]	USD 13.49 billion
Forecast Year [2030]	USD 25.21 billion
CAGR (%)	10.90%

Technology: Preference for in-vitro toxicology testing technology selection largely depends by specific research needs

Cell culture technologies serve as the cornerstone of in-vitro toxicology testing. They often involve growing cells under carefully controlled conditions to investigate the mechanisms of toxicity and predict potential toxic effects. These technologies are typically employed for realistic test models and intricate toxicity analysis. High throughput technology expedites in-vitro toxicology testing by automating sample processing and data analysis. Molecular imaging offers a non-invasive method to visualize and monitor biological processes at the cellular and molecular level, critical for understanding substance toxicity. OMICS technology, which encapsulates genomics, proteomics, and metabolomics, among others, probes into the underlying biological pathways affected by toxic substances.

Method: Cellular assays gained importance in toxicity, pharmacokinetics and pharmacodynamics in vitro toxicology testing

In-vitro toxicology testing evolves through multiple methodologies, each playing a crucial role in determining the toxicity of substances and developing safer pharmaceutical compounds. In in-vitro toxicology testing, biochemical assays are the most favored methods by pharmaceutical, biotech, and research institutions since they involve detailed investigation of the interactions between a target and a small molecule. This technique predominantly focuses on identifying potential toxic substances early, making it cost and time-efficient. Biochemical assays such as enzymatic assays, receptor-binding assays, and second messenger assays provide necessary insights into the nature of these interactions and potential impacts. Cellular assays hold an imperative space in in-vitro toxicology testing by providing a panoramic view of the cell's response to a compound or a treatment. They score high on need-based preference as they mimic human physiology more accurately. These assays help determine new compounds' toxicity, pharmacokinetics, and pharmacodynamics. Ex-vivo methods, using organotypic or slice cultures of tissues, are favored for safety evaluations, especially for organ-specific toxicity testing. In Silico processes utilize computer-simulated models for toxicity evaluation, a burgeoning preference owing to their non-invasive, cost-effective, and speedy testing abilities.

Application: Rising focus on improving testing methods while delivering accurate, reliable results catering to industry-specific requirements

Dermal toxicity gained importance due to the growing use of skin-related products and chemicals across industries due to 3D human skin model creation and reducing the dependence on animal testing. The endocrine disruption domain studies substances that can cause hormonal imbalances, impacting health and development. Major healthcare vendors collaborate with environmental agencies to boost screening of potential endocrine disruptors, encouraging chemical and ecological toxicity control industries. Ocular toxicity involves studying substances that can harm eye tissue, as it provides accurate and reproducible ocular toxicity testing products, ensuring greater safety for eye-specific products. Systemic toxicology evaluates the impact of substances on various body systems. This testing solution is a novel service for assessing organ toxicity risks, reducing costs and development time in drug manufacturing. Overall, in-vitro toxicology testing offers significant safety evaluation potential with vast growth opportunities. The last two years saw remarkable advancements aimed at improving testing methods while delivering accurate, reliable results catering to industry-specific requirements.

End-Use: In vitro testing used vigorously in food and pharma sectors to ensure safety standards

In-vitro toxicology trials ensure safety across diverse sectors, with specific methods adopted for each industry to address their different needs. Chemical corporations continually advance in-vitro evaluations to ascertain hazardous effects and safeguard human health and the ecosystem by releasing a specialized in-vitro testing platform for chemical profiling. Consumer product industries take advantage of toxicology tests to guarantee customer safety while analyzing allergenicity and irritancy in skincare and household items. Food manufacturers employ in-vitro toxicology testing for the safety evaluation of their additives through advanced in-vitro testing kits for pathogen identification. Critical for drug discovery, in-vitro testing in pharmacy facilitates the understanding of toxicity and efficacy by utilizing its in-vitro offerings. Enhancement of safety standards and customer trust can be attributed significantly to in-vitro toxicology testing, with each advancement mirroring the evolving industry needs.

Regional Insights

The Americas, particularly the U.S., and Canada, spearheading the in vitro toxicology testing field due to high biomedical research demand from high chronic disease prevalence. Government initiatives and the robust presence of market leaders further bolster their position. Europe also leans towards in-vitro testing, with legislation including Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) law spurring investment into efficient and reliable testing methods, especially for hazard identification and risk assessment. Despite being nascent, the Middle East and Africa also demonstrate a high potential market, encouraged by the increased healthcare sector investment and the pressing need to comply with global health and safety regulations. Dynamic consumer demands in the Asia Pacific, including countries such as China, Japan, and India, propel the growth of in-vitro testing in this region. For example, China's funding for biomedical research is increasing, Japan benefits from a sturdy healthcare framework and notable pro-research policies, and healthcare investors are courting India's burgeoning economy. Global initiatives, patenting activities, and research advancements, such as the EU's Horizon 2020 project and China's National Natural Science Foundation funding, underscore the indispensable role of in-vitro toxicology testing.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the In-Vitro Toxicology Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the In-Vitro Toxicology Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the In-Vitro Toxicology Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioIVT LLC, Charles River Laboratories International, Inc., Creative Bioarray, ERBC Group, Eurofins Scientific SE, Evotec SE, F. Hoffmann-La Roche AG, Gentronix Limited, HD Biosciences Co., Ltd., INDIGO Biosciences, Inc., Inotiv, Inc., InSphero AG, Intertek Group PLC, Laboratory Corporation of America Holdings, LAUS GmbH, LGC Limited, Merck KGaA, Microbac Laboratories Inc., Oroxcell SAS, Promega Corporation, Qiagen N.V., SGS SA, Thermo Fisher Scientific Inc., Toxys, Inc., Vimta Labs Ltd., and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the In-Vitro Toxicology Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Cell Culture Technology
- High Throughput Technology
- Molecular Imaging
- OMICS Technology

Method
- Biochemical Assay
- Cellular Assay
- Ex-vivo
- In Silico

Application
- Dermal Toxicity
- Endocrine Disruption
- Occular Toxicity
- Systemic Toxicology

End-User Industry
- Chemicals
- Cosmetic & Household Products
- Food
- Pharmaceuticals & Biopharmaceuticals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the In-Vitro Toxicology Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the In-Vitro Toxicology Testing Market?

3. What are the technology trends and regulatory frameworks in the In-Vitro Toxicology Testing Market?

4. What is the market share of the leading vendors in the In-Vitro Toxicology Testing Market?

5. Which modes and strategic moves are suitable for entering the In-Vitro Toxicology Testing Market?

Product Code: MRR-A339DAEFAF18

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. R&D initiatives for drug discovery and launch of novel agrochemicals and food additives
  - 5.1.1.2. Utilization of in-vitro toxicology testing for evaluation of medical devices
- 5.1.2. Restraints
  - 5.1.2.1. Technical limitations and inability to accurately replicate certain biological phenomena
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in in-vitro toxicology testing and adoption of computational biology for analyzing toxicology data
  - 5.1.3.2. Government programs to promote cruelty-free testing methods and develop novel toxicology assays
- 5.1.4. Challenges
  - 5.1.4.1. Chances of drug approval failures with the current models.
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Preference for in-vitro toxicology testing technology selection largely depends by specific research needs
- 5.2.2. Method: Cellular assays gained importance in toxicity, pharmacokinetics and pharmacodynamics in vitro toxicology testing
- 5.2.3. Application: Rising focus on improving testing methods while delivering accurate, reliable results catering to industry-specific requirements
- 5.2.4. End-Use: In vitro testing used vigorously in food and pharma sectors to ensure safety standards
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. In-Vitro Toxicology Testing Market, by Technology

6.1. Introduction
6.2. Cell Culture Technology
6.3. High Throughput Technology
6.4. Molecular Imaging
6.5. OMICS Technology

7. In-Vitro Toxicology Testing Market, by Method

7.1. Introduction
7.2. Biochemical Assay
7.3. Cellular Assay
7.4. Ex-vivo
7.5. In Silico

8. In-Vitro Toxicology Testing Market, by Application

8.1. Introduction
8.2. Dermal Toxicity
8.3. Endocrine Disruption
8.4. Occular Toxicity
8.5. Systemic Toxicology

9. In-Vitro Toxicology Testing Market, by End-User Industry

9.1. Introduction
9.2. Chemicals
9.3. Cosmetic & Household Products
9.4. Food
9.5. Pharmaceuticals & Biopharmaceuticals

10. Americas In-Vitro Toxicology Testing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific In-Vitro Toxicology Testing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa In-Vitro Toxicology Testing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. LGC Clinical Diagnostics Acquires QC Product Maker Kova International
- 13.3.2. ERBC Group Extends its Preclinical Expertise with the Acquisition of Oncofactory
- 13.3.3. IIVS and Toxys Entered into an Agreement to Offer ToxTracker for In-Vitro Genetic Toxicity Evaluation
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio